Literature DB >> 21890754

Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects.

Amar Safdar1, Donald Armstrong.   

Abstract

Infections are common in patients with hematologic neoplasms and following allogeneic hematopoietic transplantation. Neutropenia and defects in adaptive B-cell-mediated immunity and/or lack of splenic function predispose patients to a host of diverse and often serious infections. It is important to recognize that patients who undergo treatment for hematologic neoplasms may have mixed immune defects, and their vulnerability to infection may continue to change, in part as a reflection of the dynamic developments in the practice of oncology. The main obstacle in providing targeted, evidence-based antimicrobial treatment is the unpredictable results of even the new generation of diagnostic assays. A definite diagnosis for most end-organ opportunistic diseases requires tissue samples that are seldom available. Because immune defects may coexist, empirical therapy is directed toward a wide spectrum of pathogens. Real-time information about innate and adaptive immune functions and the role of acute and chronic phase molecules may improve target-specific therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890754     DOI: 10.1093/cid/cir492

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases.

Authors:  S-I Kimura; T Murata; Y Akahoshi; H Nakano; T Ugai; H Wada; R Yamasaki; Y Ishihara; K Kawamura; K Sakamoto; M Ashizawa; M Sato; K Terasako-Saito; H Nakasone; M Kikuchi; R Yamazaki; S Kako; J Kanda; A Tanihara; J Nishida; Y Kanda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-11       Impact factor: 3.267

2.  Impact of neutropenia on the clinical outcomes of Staphylococcus aureus bacteremia in patients with hematologic malignancies: a 10-year experience in a tertiary care hospital.

Authors:  Byung-Han Ryu; Seung Cheol Lee; Minjeong Kim; Yewon Eom; Jiwon Jung; Min Jae Kim; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-10       Impact factor: 3.267

3.  Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.

Authors:  Andreas F Widmer; Winfried V Kern; Jan A Roth; Markus Dettenkofer; Tim Goetting; Hartmut Bertz; Christian Theilacker
Journal:  Infection       Date:  2019-06-11       Impact factor: 3.553

4.  Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center.

Authors:  L Nesher; F P Tverdek; S N Mahajan; R F Chemaly; Kenneth V I Rolston
Journal:  Infection       Date:  2015-05-01       Impact factor: 3.553

5.  Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation.

Authors:  Seiichiro Katagiri; Moritaka Gotoh; Kazuya Tone; Daigo Akahane; Yoshikazu Ito; Kazuma Ohyashiki; Koichi Makimura
Journal:  Int J Hematol       Date:  2016-02-15       Impact factor: 2.490

6.  In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.

Authors:  Kenneth V I Rolston; Weiqun Wang; Lior Nesher; Samuel A Shelburne; Randall A Prince
Journal:  J Antibiot (Tokyo)       Date:  2015-12-02       Impact factor: 2.649

Review 7.  Antibiotic-resistant gram-negative bacterial infections in patients with cancer.

Authors:  Federico Perez; Javier Adachi; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 8.  Drug Allergy Delabeling Programs: Recent Strategies and Targeted Populations.

Authors:  Karen M Anstey; Lulu Tsao; Iris M Otani
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-15       Impact factor: 8.667

9.  [Initial patient assessment of infectious diseases and diagnostic steps with fever].

Authors:  A Schibli; M Weisser; R Bingisser; A F Widmer; M Battegay
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

10.  Fatal Infections Among Cancer Patients: A Population-Based Study in the United States.

Authors:  Yongqiang Zheng; Ying Chen; Kaixu Yu; Yun Yang; Xindi Wang; Xue Yang; Jiaxin Qian; Ze-Xian Liu; Bian Wu
Journal:  Infect Dis Ther       Date:  2021-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.